Abbisko Cayman Limited (HK:2256)

:2256

2256

Abbisko Cayman Limited

RESEARCH TOOLSreports

Want to see HK:2256 full AI Analyst Report?

Abbisko Cayman Limited (2256) Price & Analysis

6 Followers

2256 Stock Chart & Stats

HK$13.02

-HK$0.08(-1.77%)

At close: Jan 09 4:00 PM EST

HK$13.02

-HK$0.08(-1.77%)

Day’s Range― - ―

52-Week RangeHK$8.34 - HK$19.78

Previous CloseN/A

Volume927.00K

Average Volume (3M)4.32M

Market Cap

HK$6.58B

Enterprise ValueHK$5.14B

Total Cash (Recent Filing)HK$2.38B

Total Debt (Recent Filing)HK$17.77M

Price to Earnings (P/E)21.1

Beta1.29

Next Earnings

Aug 18, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.24

Shares Outstanding724,205,300

10 Day Avg. Volume4,319,715

30 Day Avg. Volume4,318,146

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)3.79

Price to Sales (P/S)12.24

P/FCF Ratio98.97

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$18.74

Price Target Upside43.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.34

Revenue Forecast (FY)HK$404.90M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe preliminary data for a subset of patients treated with pimicotinib 20 mg QD demonstrated a 64% overall response rate with responses observed in all affected organs.

Pipeline DevelopmentCompany advances oncology pipeline, initiating a registrational study for irpagratinib in hepatocellular carcinoma.

Regulatory ApprovalThe company announced acceptance of the pimicotinib NDA in China for Tenosynovial Giant Cell Tumor, with an expedited review and Merck KGaA opted-in to commercialize pimicotinib in the US/EU.

Bears Say

Market CompetitionThe company is continuing to develop ABSK043 in combination therapies for various cancers, indicating a robust pipeline.

Regulatory ChallengesThe company highlighted the latest dataset for pimicotinib in Chronic Graft-versus-Host Disease patients who either progressed or did not respond to at least one prior line of therapy.

Safety ConcernsKey updates include guidance on a clinical development plan for pimicotinib in Chronic Graft-versus-Host Disease, an IND filing for ABSK141, a preliminary safety readout for ABSK043, and preliminary safety data for ABSK121.

Abbisko Cayman Limited News

Abbisko Showcases Advanced Modeling for Liver Cancer Drug ABSK-011 at European Meeting

Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an update. Abbisko Therapeutics has presented two advances in model-based...

11d ago

2256

Abbisko Shareholders Back All AGM Resolutions, Bolstering Capital and Governance Flexibility

Abbisko Cayman Limited ( ($HK:2256) ) has shared an update. Abbisko Cayman Limited reported that shareholders approved all...

26d ago

2256

Abbisko Cayman Raises HK$517 Million Through Share Placing to Fund Drug Development

Abbisko Cayman Limited ( ($HK:2256) ) has provided an update. Abbisko Cayman Limited has completed a placing of...

2M ago

2256

Abbisko Moves to Modernise Governance With Digital-Ready Articles Update

Abbisko Cayman Limited ( ($HK:2256) ) has provided an update. Abbisko Cayman Limited plans to amend its existing...

2M ago

2256

Abbisko Cayman Sets 2026 AGM to Approve Results, Board Changes and 20% Share Issue Mandate

Abbisko Cayman Limited ( ($HK:2256) ) has issued an update. Abbisko Cayman Limited has convened its annual general...

2M ago

2256

Abbisko Showcases Broad Oncology Pipeline with Pan‑KRAS Data at 2026 AACR

Abbisko Cayman Limited ( ($HK:2256) ) has provided an update. Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited,...

2M ago

2256

Abbisko Cayman to Raise HK$517 Million via Discounted Share Placing for R&D Push

Abbisko Cayman Limited ( ($HK:2256) ) has shared an update. Abbisko Cayman Limited has launched a share placing...

2M ago

2256

Abbisko Grants 290,000 Share Options to Employees Under Post-IPO Scheme

Abbisko Cayman Limited ( ($HK:2256) ) has shared an announcement. Abbisko Cayman Limited has granted 290,000 share options...

2M ago

2256

Abbisko Wins EMA Orphan Drug Status for Liver Cancer Therapy Irpagratinib

Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an announcement. Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited,...

3M ago

2256

Abbisko Wins FDA IND Clearance for Pediatric Achondroplasia Drug ABSK061

Abbisko Cayman Limited ( ($HK:2256) ) has provided an update. Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited,...

3M ago

2256

2256 FAQ

What was Abbisko Cayman Limited’s price range in the past 12 months?

Abbisko Cayman Limited lowest stock price was HK$8.34 and its highest was HK$19.78 in the past 12 months.

What is Abbisko Cayman Limited’s market cap?

Abbisko Cayman Limited’s market cap is HK$6.58B.

When is Abbisko Cayman Limited’s upcoming earnings report date?

Abbisko Cayman Limited’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.

How were Abbisko Cayman Limited’s earnings last quarter?

Abbisko Cayman Limited released its earnings results on Mar 02, 2026. The company reported -HK$0.494 earnings per share for the quarter, missing the consensus estimate of -HK$0.448 by -HK$0.046.

Is Abbisko Cayman Limited overvalued?

According to Wall Street analysts Abbisko Cayman Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abbisko Cayman Limited pay dividends?

Abbisko Cayman Limited does not currently pay dividends.

What is Abbisko Cayman Limited’s EPS estimate?

Abbisko Cayman Limited’s EPS estimate is -0.39.

How many shares outstanding does Abbisko Cayman Limited have?

Abbisko Cayman Limited has 724,205,300 shares outstanding.

What happened to Abbisko Cayman Limited’s price movement after its last earnings report?

Abbisko Cayman Limited reported an EPS of -HK$0.494 in its last earnings report, missing expectations of -HK$0.448. Following the earnings report the stock price went down -6.53%.

Which hedge fund is a major shareholder of Abbisko Cayman Limited?

Currently, no hedge funds are holding shares in HK:2256

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Abbisko Cayman Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

11.49%

Trailing 12-Months

Asset Growth

16.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abbisko Cayman Limited

Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.

Abbisko Cayman Limited (2256) Earnings & Revenues

Historic Earnings Reports

2256 Stock 12 Month Forecast

Average Price Target

HK$18.74

▲(43.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"HK$8","19":"HK$19","10.75":"HK$10.75","13.5":"HK$13.5","16.25":"HK$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$18.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$18.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,10.75,13.5,16.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,10.22923076923077,10.938461538461539,11.647692307692306,12.356923076923076,13.066153846153846,13.775384615384613,14.484615384615383,15.193846153846152,15.903076923076922,16.61230769230769,17.32153846153846,18.03076923076923,{"y":18.74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,10.22923076923077,10.938461538461539,11.647692307692306,12.356923076923076,13.066153846153846,13.775384615384613,14.484615384615383,15.193846153846152,15.903076923076922,16.61230769230769,17.32153846153846,18.03076923076923,{"y":18.74,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,10.22923076923077,10.938461538461539,11.647692307692306,12.356923076923076,13.066153846153846,13.775384615384613,14.484615384615383,15.193846153846152,15.903076923076922,16.61230769230769,17.32153846153846,18.03076923076923,{"y":18.74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.49,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >